# Andrea Necchi

Source: https://onco.cc/people/andrea-necchi/  
OnCo record `andrea-necchi` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led PURE-01, the first neoadjuvant pembrolizumab trial in bladder cancer, and now leads bladder-preserving immunotherapy studies.

## Summary

Andrea Necchi led PURE-01, which showed neoadjuvant pembrolizumab alone produces pathological complete responses in more than a third of muscle-invasive bladder cancers and defined biomarkers of response, and is a lead investigator of the KEYNOTE-057 and SunRISe programmes in non-muscle-invasive disease. He heads GU oncology at San Raffaele and studies bladder-sparing strategies.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: urothelial; neoadjuvant; italy
- Role: Head of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital; Professor, Vita-Salute San Raffaele University
- Specialisms: Urothelial cancer; Neoadjuvant immunotherapy; Bladder preservation; Non-muscle-invasive disease

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Necchi%20A%5BAuthor%5D%20bladder%20pembrolizumab

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [IRCCS Ospedale San Raffaele](https://onco.cc/institutions/san-raffaele/)
- trials: [SunRISe-1](https://onco.cc/trials/sunrise-1/)
- key papers: [SunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer](https://onco.cc/key-papers/paper-sunrise-1-jco-2025/)
- journals: [European Urology](https://onco.cc/journals/european-urology/)

---
JSON: https://onco.cc/api/v1/entities/andrea-necchi.json